NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/18/2024
Back to search
Official data from USPTO
ENTRADA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
06/18/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
05/07/2020
Registration date
06/18/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/18/2024
Last transaction
06/18/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/14/2022
First use in commerce
06/14/2022
Drawing code
3
Owner type
03
Owner location
Boston, MA
Examiner
SOLANO, CARLITA
Law office
O10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a design of five curved lines. The center of each line meets at the right side of the design, and the lines fan out to the left both above and below the center, forming an overall shape that resembles a curved arrow pointing to the right. The lines increase in width from left to right. To the right of the design is the stylized word "ENTRADA", with the stylized word "THERAPEUTICS" underneath.
Holders and representatives
Holders
Entrada Therapeutics, Inc.
Representatives
Stephanie H. Bald Kelly IP, LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
House mark for a full line of pharmaceuticalsbut not including pharmaceuticals intended to treat multiple sclerosis or related diseases or conditions related to multiple sclerosisall of the foregoing specifically excluding pharmaceutical preparations for the treatment of cancer
Class 42
Pharmaceutical research and development services
Publications
History of USPTO decisions and trademark events.
51 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/18/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/13/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/13/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/16/2024
IUAF
USE AMENDMENT FILED
04/11/2024
EISU
TEAS STATEMENT OF USE RECEIVED
04/11/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/14/2023
EX5G
SOU EXTENSION 5 GRANTED
11/13/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/13/2023
EXT5
SOU EXTENSION 5 FILED
11/07/2023
EEXT
SOU TEAS EXTENSION RECEIVED
11/07/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/24/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/24/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/24/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/24/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/24/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/20/2023
EX4G
SOU EXTENSION 4 GRANTED
04/18/2023
EXT4
SOU EXTENSION 4 FILED
04/18/2023
EEXT
SOU TEAS EXTENSION RECEIVED
04/18/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/26/2022
EX3G
SOU EXTENSION 3 GRANTED
10/24/2022
EXT3
SOU EXTENSION 3 FILED
10/24/2022
EEXT
SOU TEAS EXTENSION RECEIVED
10/24/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/16/2022
EX2G
SOU EXTENSION 2 GRANTED
04/14/2022
EXT2
SOU EXTENSION 2 FILED
04/14/2022
EEXT
SOU TEAS EXTENSION RECEIVED
04/14/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/29/2021
EX1G
SOU EXTENSION 1 GRANTED
10/27/2021
EXT1
SOU EXTENSION 1 FILED
10/27/2021
EEXT
SOU TEAS EXTENSION RECEIVED
10/27/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/21/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/21/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/21/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/11/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/16/2021
PUBO
PUBLISHED FOR OPPOSITION
03/16/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/24/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/07/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/05/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/10/2020
GNRT
NON-FINAL ACTION E-MAILED
08/10/2020
CNRT
NON-FINAL ACTION WRITTEN
08/10/2020
DOCK
ASSIGNED TO EXAMINER
08/04/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
05/22/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/21/2020
NWAP
NEW APPLICATION ENTERED
05/11/2020
Continuous trademark protection
Get notified about every new filing that threatens ENTRADA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.